Skip to Content

Join the 'Yervoy' group to help and get support from people like you.

Yervoy News

FDA Expands Approval of Yervoy (ipilimumab) to Include Pediatric Patients 12 Years and Older with Unresectable or Metastatic Melanoma

Posted 25 Jul 2017 by Drugs.com

PRINCETON, N.J.--(BUSINESS WIRE) July 24, 2017 --Bristol-Myers Squibb Company (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) has expanded the indication for Yervoy (ipilimumab) injection for intravenous use to now include the treatment of unresectable or metastatic melanoma in pediatric patients 12 years of age and older. Yervoy was evaluated in two trials of ...

More Patients OK'd for Cancer Trials Under Obamacare: Study

Posted 20 Jul 2017 by Drugs.com

THURSDAY, July 20, 2017 – The Affordable Care Act has enabled more privately insured patients to enroll in clinical trials for new cancer treatments, a new study contends. Speedy approvals are important for patients who want to participate in clinical trials, said study author Dr. David Hong. He's deputy chair of investigational cancer therapeutics at the University of Texas MD Anderson Cancer ...

Publicly Funded Cancer Trials Gained Americans 3 Million More Years

Posted 6 Jun 2017 by Drugs.com

TUESDAY, June 6, 2017 – Public-funded trials have significantly extended the lives of people diagnosed with cancer, according to new research. SWOG, the clinical trials network funded by the U.S. National Cancer Institute (NCI), has involved more than 200,000 patient volunteers. These trials have led to approval of 14 new cancer drugs and more than 100 changes to cancer care standards. All told, ...

Powerful Cancer Drugs Linked to Rare Heart Risks

Posted 3 Nov 2016 by Drugs.com

THURSDAY, Nov. 3, 2016 – In rare cases, potent drugs that prompt the immune system to fight cancer may threaten the heart in the process, researchers report. Known as immunotherapy, these medications have transformed cancer treatment in recent years, sending some patients who had few options left into remission. But a report in the Nov. 3 issue of New England Journal of Medicine describes two ...

Arthritis Possible Side Effect of Certain Cancer Drugs: Study

Posted 29 Jun 2016 by Drugs.com

TUESDAY, June 28, 2016 – Certain cancer immunotherapy drugs may increase risk for joint and tissue disease, including arthritis, new research suggests. "We keep having referrals coming in from our oncologists as more patients are treated with these drugs," said Dr. Clifton Bingham, director of the Johns Hopkins Arthritis Center in Baltimore. "In particular, as more patients are treated with ...

U.S. Pays Highest Prices for Cancer Meds: Study

Posted 6 Jun 2016 by Drugs.com

MONDAY, June 6, 2016 – The United States pays the highest prices in the world for generic and brand-name cancer drugs, a new study has found. However, as the world's wealthiest nation, the United States is better able to pay for those pricey drugs than poorer countries with somewhat lower medication prices, added study lead author Dr. Daniel Goldstein. People in China and India are much less ...

'Precision' Cancer Treatment May Extend Lives

Posted 20 May 2016 by Drugs.com

THURSDAY, May 19, 2016 – "Precision" cancer treatment that's guided by genetic clues from the patient's own tumor appears to outperform traditional chemotherapy, a new research review finds. Patients given precision – or personalized – treatment experienced a tumor shrinkage rate six times that attained by regular chemotherapy. But, that only happened if doctors used genetic information to ...

Bristol-Myers Squibb’s Opdivo (nivolumab) + Yervoy (ipilimumab) Regimen Receives Expanded FDA Approval in Unresectable or Metastatic Melanoma Across BRAF Status

Posted 24 Jan 2016 by Drugs.com

PRINCETON, N.J., January 23, 2016 --(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the treatment of patients with BRAF V600 wild-type and BRAF V600 mutation-positive unresectable or metastatic melanoma.1 This indication is approved under ...

Fewer Childhood Cancer Survivors Dying From 'Late' Effects

Posted 13 Jan 2016 by Drugs.com

WEDNESDAY, Jan. 13, 2016 – Fewer childhood cancer survivors are dying years later from lingering effects of the treatment that conquered their cancer, a new study finds. Experts called the report, published in the Jan. 14 issue of the New England Journal of Medicine, "very good news." "The findings substantiate what experts in the field have hoped would be true," said lead researcher Dr. Gregory ...

FDA Approves Expanded Use for Melanoma Drug

Posted 29 Oct 2015 by Drugs.com

THURSDAY, Oct. 29, 2015 – The melanoma drug Yervoy (ipilimumab) can now be used to reduce the risk of the deadly skin cancer returning after surgery, the U.S. Food and Drug Administration said Thursday. The expanded use of this intravenous drug is an adjunct therapy for patients with stage 3 melanoma, in which the cancer has reached one or more lymph nodes. Patients with this stage of melanoma ...

FDA Approves Yervoy to Reduce the Risk of Melanoma Returning after Surgery

Posted 28 Oct 2015 by Drugs.com

October 28, 2015 – Today the U.S. Food and Drug Administration expanded the approved use of Yervoy (ipilimumab) to include a new use as adjuvant therapy for patients with stage III melanoma, to lower the risk that the melanoma will return following surgery. Melanoma, the most aggressive type of skin cancer, is the leading cause of death from skin cancer. Melanoma is more likely to spread to ...

BMS Receives FDA Approval for Opdivo (nivolumab) + Yervoy (ipilimumab) Regimen in BRAF V600 Wild-Type Melanoma

Posted 1 Oct 2015 by Drugs.com

PRINCETON, N.J., October 1, 2015 --(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Opdivo (nivolumab) in combination with Yervoy (ipilimumab), for the treatment of patients with BRAF V600 wild-type unresectable or metastatic melanoma.1 Today’s announcement marks the first and only FDA approval of a Regimen of two I ...

Finding Disease Cures Can Take Up to a Century: Analysis

Posted 24 Sep 2015 by Drugs.com

THURSDAY, Sept. 24, 2015 – A team of scientists has looked back over decades of discovery to conclude that it can take dozens of years, even a century, for cumulative research to lead to a cure for a single disease. The finding is disheartening given the current U.S. government underfunding of the basic science needed to investigate diseases, said a team led by Dr. R. Sanders Williams, president ...

U.S. Oncologists Decry High Cost of Cancer Drugs

Posted 23 Jul 2015 by Drugs.com

THURSDAY, July 23, 2015 – Soaring costs for cancer drugs are hurting patient care in the United States, a group of top oncologists claim. "High cancer-drug prices are affecting the care of patients with cancer and our health care system," Dr. Ayalew Tefferi, a hematologist at Mayo Clinic in Rochester, Minn., said in a Mayo news release. Tefferi and his colleagues made a number of recommendations ...

Immune-Focused Drugs Show Promise Against Melanoma

Posted 20 Apr 2015 by Drugs.com

MONDAY, April 20, 2015 – Drugs that supercharge the body's immune system show promise in treating advanced melanoma, according to a pair of clinical trials. The trials both involve drugs called immune checkpoint inhibitors, which essentially prod the immune system to attack and destroy cancer cells, said Dr. Suzanne Topalian, director of the Melanoma Program at Johns Hopkins' Sidney Kimmel ...

Page 1 2 Next

Ask a Question

Further Information

Related Condition Support Groups

Melanoma - Metastatic, Melanoma

Yervoy Patient Information at Drugs.com